Natesan Sridhar, Svensson Kjell A, Reckless Greg E, Nobrega José N, Barlow Karen B L, Johansson Anette M, Kapur Shitij
Schizophrenia Program and PET Centre, Toronto, Ontario, Canada.
J Pharmacol Exp Ther. 2006 Aug;318(2):810-8. doi: 10.1124/jpet.106.102905. Epub 2006 Apr 28.
"Dopamine stabilizers" are a new class of compounds that have the ability to reverse both hypo- as well as hyperdopaminergia in vivo. This class, exemplified by the phenylpiperidines (S)-(-)-3-(3-methanesulfonyl-phenyl)-1-propyl-piperidine [(-)-OSU6162] and 4-(3-methanesulfonyl-phenyl)-1-propyl)-piperidine [ACR16] although lacking high in vitro binding affinity for dopamine D2 receptor [(-)-OSU6162, Ki = 447 nM; ACR16, Ki > 1 microM], shows functional actions, suggestive of their interaction. Hence, we evaluated in vivo D2 occupancy of these agents in rats and correlated it to observed effects in a series of behavioral, neurochemical, and endocrine models relevant to the dopamine system and antipsychotic effect. Both (-)-OSU6162 and ACR16 showed robust dose-dependent striatal D2 occupancy with ED50 values of 5.27 and 18.99 mg/kg s.c., respectively, and functional assays showed no partial agonism. Over an occupancy range of 37 to 87% (3-60 mg/kg) for (-)-OSU6162 and 35 to 74% (10-60 mg/kg) for ACR16, we observed both inhibitory (amphetamine-induced locomotor activity) and stimulatory effects (in habituated rats). Haloperidol, over a similar occupancy range (33-78%), potently inhibited psychostimulant activity and induced catalepsy, but it failed to activate habituated animals. In the conditioned avoidance response assay, ACR16 was clearly more efficacious than (-)-OSU6162. In addition, both these compounds demonstrated significant preferential Fos induction in the nucleus accumbens compared with the dorsolateral striatum, a strong predictor of atypical antipsychotic efficacy. The results suggest that dopamine stabilizers exhibit locomotor stabilizing as well as antipsychotic-like effects, with low motor side effect liability, in a dose range that corresponds to high D2 in vivo occupancy.
“多巴胺稳定剂”是一类新型化合物,它们能够在体内逆转多巴胺能不足以及多巴胺能亢进。以苯哌啶类化合物(S)-(-)-3-(3-甲磺酰基苯基)-1-丙基哌啶[(-)-OSU6162]和4-(3-甲磺酰基苯基)-1-丙基哌啶[ACR16]为代表的这一类化合物,尽管对多巴胺D2受体缺乏高的体外结合亲和力[(-)-OSU6162,Ki = 447 nM;ACR16,Ki>1 microM],但却表现出功能性作用,提示它们之间存在相互作用。因此,我们评估了这些药物在大鼠体内的D2占有率,并将其与在一系列与多巴胺系统及抗精神病作用相关的行为、神经化学和内分泌模型中观察到的效应相关联。(-)-OSU6162和ACR16均显示出强大的剂量依赖性纹状体D2占有率,其ED50值分别为5.27和18.99 mg/kg皮下注射,功能试验显示无部分激动作用。在(-)-OSU6162的占有率范围为37%至87%(3 - 60 mg/kg)以及ACR16的占有率范围为35%至74%(10 - 60 mg/kg)时,我们观察到了抑制作用(苯丙胺诱导的运动活性)和刺激作用(在习惯化大鼠中)。氟哌啶醇在类似的占有率范围(33% - 78%)内,能有效抑制精神兴奋活性并诱发僵住症,但未能激活习惯化动物。在条件性回避反应试验中,ACR16明显比(-)-OSU6162更有效。此外,与背外侧纹状体相比,这两种化合物在伏隔核中均表现出显著的Fos诱导优先性,这是非典型抗精神病疗效的一个有力预测指标。结果表明,多巴胺稳定剂在对应于体内高D2占有率的剂量范围内,表现出运动稳定作用以及类抗精神病作用,且运动副作用较小。